(Laval, Québec, Canada, July 15, 2015) – Algorithme Pharma, a full service provider focused on early stage clinical research with over twenty years of experience, proudly announces the addition of Dr. Anahita Keyhani to the Algorithme Pharma family. Dr. Keyhani brings almost two decades of experience to her new role as Director, Method Development, previously Senior Research Scientist at Charles River Laboratories.
Algorithme Pharma, an Altasciences company, is now a proud member of the Clinical Data Interchanges Standards Consortium (CDISC), a non-profit organization harmonizing clinical data and streamlining research processes, from protocol through analysis and reporting, including the use of electronic health records to facilitate the collection of high quality research data.
Vince & Associates Clinical Research, a premier provider of early phase clinical research services, announced the completion of CymaBay Therapeutics’ Phase II clinical trial of arhalofenate administered in combination with febuxostat (Uloric™, Takeda Pharmaceutical Company Limited) by successfully enrolling thirty two study volunteers diagnosed with gout. Arhalofenate is being tested for the treatment of gout.
Vince & Associates Clinical Research, a premier provider of early phase clinical research services, has been awarded six CRO Leadership Awards in the following categories: Quality, Productivity, Regulatory and Innovation in three sectors – Emerging Pharma, Biotech and Emerging Biotech.